Hermesdorf, Marco
Leppert, David
Maceski, Aleksandra
Benkert, Pascal
Wellmann, Jürgen
Wiendl, Heinz
Kuhle, Jens
Berger, Klaus
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_189140 / 1)
Bundesministerium für Bildung und Forschung (FKZ-01ER0816 and FKZ-01ER1506)
Westfälische Wilhelms-Universität Münster
Article History
Received: 16 May 2022
Accepted: 13 September 2022
First Online: 23 September 2022
Competing interests
: D.L. is Chief Medical Officer of GeNeuro. H.W. received grants from the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Deutsche Myasthenie Gesellschaft e.V., Alexion, Amicus Therapeutics Inc, Argenx, Biogen, CSL Behring, F. Hoffman – La Roche, Genzyme, Merck KgaA, Novartis Pharma, Roche Pharma, and UCB Biopharma. H.W. received payment or honoraria from Alexion, Amicus Therapeutics, Biogen, Biologix, Bristol Myers Squibb, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Gen Medicine, Medison, Merck, Novartis, Roche Pharma AG, Genzyme, TEVA, and WebMD Global. H.W. participated on a data safety monitoring board or advisory board for Argenx, and PSI CRO. J.K. received grants from the Swiss National Science Foundation and Octave Biosciences. J.K. received consulting fees from Biogen, Novartis, Octave, Roche, and Sanofi. K.B. received grants from the BMBF. All other authors have no competing interest to declare.